Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 5;70(12):3679–3692. doi: 10.1007/s00262-021-03024-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Progression-free survival and overall survival in the overall study population or according to GX301 regimens. a Progression-free survival in the overall study population. Number of censored cases before the end of observation: 16; number of progressions by day 540: 82; time to progression: 163 days (IQR: 95–183); estimated Progression-free survival: 77.3% at day 90, 29.5% at day 180, 10.7% at day 270. b Progression-free survival according to GX301 regimens. Median times to progression (IQR) for regimen 1, regimen 2 and regimen 3 were, respectively, 150 days (102–179), 176 days (105–187) and 128 days (88–181). c Overall survival in the overall study population. Number of censored cases before the end of observation: 49; number of deaths by day 720: 49; median time to death (IQR): 698 (452-not reached); estimated survival: 99% at day 180, 84% at day 360, 62% at day 540, 48% at day 720. d Overall survival according to GX301 regimens. Numbers of deaths by day 720 were for regimen 1, regimen 2 and regimen 3 were 16, 14 and 19, respectively; median times to death (IQR) for regimen 1, regimen 2 and regimen 3 were, respectively, 698 (367-not reached), not determined (503-not reached), 654 (474-not reached)